الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
B
reast cancer is the second most common malignancy among female patients. Early breast cancer is considered potentially curable.
Immunohistochemistry has an important role in the pathology of breast disease. It is widely used to localize specifically proteins in cells and tissues.
Ki-67, a marker of cell proliferation, is a specific nuclear antigen expressed in all phases of the cell cycle, which can be readily detected using immunohistochemistry methods. Many guidelines and international groups concluded that measurement of Ki-67 could be important both in standard clinical practice and within clinical trials.
A recently published meta-analysis reported that a high Ki-67 level was associated with a high pCR rate. Our results demonstrate that patients with a Ki-67 are more sensitive to NCT, have higher pCR rates, and benefit more from NCT compared to those with a low Ki-67. However, it remains unclear whether other factors such as therapy regimens and cycles of NCT, the clinical stage, and tumor location have an impact on Ki-67-based health outcomes.